Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer

April 8th 2025

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

R-DA-EDOCH/R-DHAP Induction Yields Responses and MRD Negativity in Young, High-Risk MCL Population

April 8th 2025

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

Dr Zhang on the Rationale of Evaluating SIM0270/Everolimus in ER+/HER2– Advanced Breast Cancer

April 7th 2025

Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance

April 7th 2025

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Dr Pietrantonio on Future Directions of Evaluating Amivantamab in CRC

April 4th 2025

Filippo Pietrantonio, MD, highlights the future directions of assessing amivantamab with or without chemotherapy in patients with colorectal cancer.

Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

April 3rd 2025

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

April 3rd 2025

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

April 3rd 2025

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC

April 2nd 2025

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma

April 1st 2025

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

MDC-CAR-BCMA001 Shows Efficacy, Safety as Compassionate Use in R/R Multiple Myeloma and AL Amyloidosis

April 1st 2025

MDC-CAR-BCMA001 may be a suitable construct for the treatment of BCMA-pretreated patients with triple-class refractory multiple myeloma or AL amyloidosis.

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

April 1st 2025

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

Tisotumab Vedotin Earns European Approval for Pretreated Recurrent/Metastatic Cervical Cancer

April 1st 2025

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer

April 1st 2025

Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma

March 31st 2025

D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.

Dr Oluwole on AE Mitigation Following Axi-Cel in R/R LBCL

March 31st 2025

Olalekan O. Oluwole, MD, MPH, details the importance of early intervention regarding adverse effects following CAR T products in relapsed/refractory LBCL.

Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma

March 31st 2025

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

TTFields/Paclitaxel Fails to Boost OS in Platinum-Resistant Ovarian Cancer But Shows Potential in Key Subgroup

March 26th 2025

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.